A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor

A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in the lungs, of GSK3008348, a novel inhaled alpha-v beta-6 (αvβ6) int...

Full description

Bibliographic Details
Main Authors: Toby M. Maher, Juliet K. Simpson, Joanna C. Porter, Frederick J. Wilson, Robert Chan, Rhena Eames, Yi Cui, Sarah Siederer, Simon Parry, Julia Kenny, Robert J. Slack, Jagdeep Sahota, Lyn Paul, Peter Saunders, Philip L. Molyneaux, Pauline T. Lukey, Gaia Rizzo, Graham E. Searle, Richard P. Marshall, Azeem Saleem, Arthur R. Kang’ombe, David Fairman, William A. Fahy, Mitra Vahdati-Bolouri
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Respiratory Research
Subjects:
Alpha-v beta-6
αvβ6
Integrin
Idiopathic pulmonary fibrosis
IPF, positron emission tomography
PET
Online Access:http://link.springer.com/article/10.1186/s12931-020-01339-7

Internet

http://link.springer.com/article/10.1186/s12931-020-01339-7

Similar Items